- Policy
- HIRA clears all Strensiq pre-approvals from July
- by Lee, Hye-Kyung Sep 2, 2020 06:18am
- Handok’s rare disease treatment Strensiq injection (asfotase alfa) passed the preliminary approval review and processed the first reimbursed administration. Listed for healthcare reimbursement as of June 1, Strensiq is a third drug to be required to receive pre-administration approval for a reimbursed use of the drug. Soliris injection (ecu
- Company
- Forxiga by AstraZeneca appeals against Dong-A ST
- by Kim, Jin-Gu Sep 2, 2020 06:18am
- AstraZeneca, which failed in the first round of the patent dispute over the SGLT-2 inhibitor-based diabetes treatment, Forxiga (Dapagliflozin), launched a counterattack against Dong-A ST. It disagrees with the trial decision of the Patent Tribunal, who sided with the generic company, and filed a lawsuit to the Patent Court of Korea to canc
- Company
- Indication of Alunbrig expanded as ALK-positive lung cancer
- by Sep 2, 2020 06:18am
- The indication has been expanded as the first line treatment of Takeda Pharmaceutical Korea's lung cancer treatment, Alunbrig. Takeda Pharmaceutical Korea (CEO Moon Hee-seok) announced on the 28th that The MFDS approved Alunbriq (Brigatinib), an anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer drug, to expand its indica
- Company
- Now, a transition of power in the contraceptive market
- by Sep 1, 2020 06:13am
- The domestic over-the-counter (OTC) pre-contraceptive market, which was almost monopolized by imported finished products, is showing mixed trend. Sales of top-tier products such as Myvlar have been sold out for a long period of time, resulting in a sharp decrease in sales, and recently released products are fiercely competing, causing changes.
- Company
- “Cosidering PPI when prescribing NOAC in high-risk patient"
- by Eo, Yun-Ho Sep 1, 2020 06:13am
- Already, it has been ten years since new oral anticoagulant (NOAC) has launched in the South Korean market. Experts are actively discussing the practical use of NOAC as relevant prescription records have been accumulated. Regarding the off-label prescription of the drug, the interest has heightened recently on optimizing the dose and ble
- Company
- GC-Novartis report COVID-19 cases, all other test negative
- by Kim, Jin-Gu Sep 1, 2020 06:12am
- Although confirmed cases of COVID-19 were reported from GC Pharma and Novartis Korea, sources confirmed others in the companies were not further infected. According to pharmaceutical industry sources on Aug. 28, all workers, who had a close contact with the confirmed cases in the same department or in the vicinity at GC Pharma and Novartis K
- Policy
- Generic for Xeljanz by Boryung was first approved
- by Lee, Tak-Sun Sep 1, 2020 06:12am
- Boryeong's generic for Xeljanz was first approved. On the 27th, the MFDS granted Boryung Tofacitinib 5mg (Tofacitinib aspartate) by Boryung as a drug for data-based re-evaluation. This product is a salt-modified product of the original product Gelzanz 5mg (Tofacitinib citrate), which was approved in April 2014, and is the first approved pr
- Policy
- Ongentys listed at ₩2,515 & Prevymis at ₩145,000
- by Kim, Jung-Ju Sep 1, 2020 06:12am
- SK Chemicals' parkinson's syndrome treatment, Ongentys 50mg (Opicapone) will be listed at &8361;2,515 per capsule starting October 1st. MSD Korea's CMV infection and disease prevention drug Prevymis (Letermovir) 240mg was listed at &8361;145,000, and Ferring Korea's infertility treatment, Rekovelle PFS (Follitropin delta) is applied at &83
- Company
- New HIV drug Biktarvy sales of ₩20 billion in one year
- by Kim, Jin-Gu Aug 31, 2020 05:58am
- It is confirmed that Gilead Science's new HIV treatment, Biktarvy, made close to &8361;20 billion in a year after it entered the market in earnest. According to the analysis, Gilead is maintaining the leadership in the HIV treatment market due to the rapid growth of Biktarvy. ◆Biktarvy, sales of &8361;14.4 billion in the first half of
- InterView
- KRPIA “Narrowing the gap with gov. on appropriate pricing"
- by Eo, Yun-Ho Aug 31, 2020 05:57am
- Surely, the number one value of the pharmaceutical industry is ‘new drug.’ And the multinational pharmaceutical companies’ interests are more focused on the ‘adequate value of new drug’ than ever. As the age of ‘high-cost drug’ has emerged, the government and the pharmaceutical industry’s discrepancy when viewing the drug pricing
